Karyopharm Therapeutics Inc (NASDAQ:KPTI) Receives $19.33 Consensus PT from Analysts

Shares of Karyopharm Therapeutics Inc (NASDAQ:KPTI) have earned an average rating of “Buy” from the nine brokerages that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $19.33.

Several brokerages have issued reports on KPTI. Robert W. Baird set a $25.00 target price on Karyopharm Therapeutics and gave the company a “buy” rating in a report on Tuesday, September 24th. ValuEngine upgraded Karyopharm Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, September 5th. BidaskClub upgraded Karyopharm Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday. HC Wainwright restated a “buy” rating and issued a $32.00 target price (up from $29.00) on shares of Karyopharm Therapeutics in a report on Friday, July 5th. Finally, Zacks Investment Research cut Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday.

NASDAQ:KPTI traded up $0.34 during trading hours on Tuesday, hitting $10.45. The company had a trading volume of 1,453,055 shares, compared to its average volume of 1,793,735. The company has a current ratio of 6.93, a quick ratio of 6.93 and a debt-to-equity ratio of 1.46. The company has a 50-day moving average of $9.95 and a 200 day moving average of $7.39. The company has a market cap of $647.07 million, a P/E ratio of -3.33 and a beta of 2.42. Karyopharm Therapeutics has a 1 year low of $3.92 and a 1 year high of $13.52.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its earnings results on Tuesday, August 6th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.97) by $0.26. The company had revenue of $9.49 million during the quarter. Karyopharm Therapeutics had a negative return on equity of 154.75% and a negative net margin of 2,138.80%. On average, analysts forecast that Karyopharm Therapeutics will post -3.46 earnings per share for the current year.

In other news, CEO Michael Kauffman sold 10,000 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $12.00, for a total transaction of $120,000.00. Following the completion of the transaction, the chief executive officer now directly owns 539,767 shares in the company, valued at approximately $6,477,204. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Sharon Shacham sold 20,000 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $12.00, for a total value of $240,000.00. Corporate insiders own 11.63% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in KPTI. Bank of Montreal Can purchased a new position in shares of Karyopharm Therapeutics during the 2nd quarter worth $29,000. Envestnet Asset Management Inc. grew its holdings in shares of Karyopharm Therapeutics by 12.4% during the 2nd quarter. Envestnet Asset Management Inc. now owns 11,980 shares of the company’s stock worth $72,000 after purchasing an additional 1,319 shares during the period. Parametric Portfolio Associates LLC purchased a new position in shares of Karyopharm Therapeutics during the 2nd quarter worth $128,000. Premier Asset Management LLC purchased a new position in shares of Karyopharm Therapeutics during the 2nd quarter worth $160,000. Finally, UBS Asset Management Americas Inc. grew its holdings in shares of Karyopharm Therapeutics by 101.2% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 26,976 shares of the company’s stock worth $162,000 after purchasing an additional 13,571 shares during the period. Institutional investors and hedge funds own 82.58% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for
the treatment of cancer and other major diseases. Karyopharm’s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).

Featured Story: What are the Different Types of Leveraged Buyouts?

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.